Fulcrum Therapeutics, Inc.

FULC Healthcare Biotechnology

Fulcrum Therapeutics, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $80.0 million, up 2,752.0% from fiscal 2023. In the quarter to June 2026, EPS fell 21.4% and free cash flow fell 13.1%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

3.65 0.02 −0.54%
Market cap
$280.0M
P/E
0.0×
Fwd P/E
−9.4×
Dividend yield
—
F-score
5/9
Altman Z
8.22
Beneish M
21.24
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
— — — —

+8 more quarters

EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
31.35 34.33 27.40 17.70
Net Debt/EBITDA
10.96 15.26 15.77 9.33
Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(0.21) (0.25) (0.27) (0.23)
Book value per Share
4.07 4.37 5.51 3.17
Free Cash Flow
(15.70) (18.76) (16.96) (14.28)
EV/EBIT
— — — —
Other line items

Show all line items

Columns are period end dates